Simple Enterographic Activity Score for Crohn’s Disease: comparison with endoscopic, biochemical, and clinical findings

Eder, Piotr; Katulska, Katarzyna; Łykowska‐Szuber, Liliana; Stawczyk‐Eder, Kamila; Krela‐Kaźmierczak, Iwona; Linke, Krzysztof

doi:10.20452/pamw.1825

Cited by 12 publications

(25 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lately, in our institution, a score quantifying the inflammatory activity of CD in the jejunum and ileum has been proposed. This score has been called SEAS-CD, and its usefulness has been proved in a separate analysis comparing SEAS-CD results with endoscopic assessment, which stood for us as a “gold standard” [ 17 ]. That is why we decided to choose SEAS-CD, together with ileal SES-CD, as a method of choice in determining CD activity in small bowel CD.…”

Section: Discussionmentioning

confidence: 99%

“…The CD activity in the small bowel was estimated by using the Simple Enterographic Activity Score for Crohn's Disease (SEAS-CD), which was assessed by an independent radiologist who was blinded to FC results and had more than 10 years experience in this imaging method. The SEAS-CD was formulated in our institution, and the usefulness of this score in determining the activity of CD was validated in an independent CD patient group by comparing it with endoscopic assessment, which was considered a diagnostic “gold standard” ( Table I ) [ 17 ]. Endoscopic CD activity was assessed by experienced endoscopists blinded to FC results (KL, IKK, LLS) in an ileocolonoscopic study by using SES-CD [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study

Stawczyk‐Eder¹,

Eder²,

Łykowska‐Szuber³

et al. 2015

aoms

Self Cite

View full text Add to dashboard Cite

IntroductionThere are data suggesting that the diagnostic usefulness of faecal calprotectin (FC) may vary depending on the Crohn's disease (CD) location. The aim of the study was to compare the diagnostic usefulness of FC in CD patients with different disease locations.Material and methodsWe prospectively enrolled 120 CD patients in the study. Disease activity was assessed by using Crohn's Disease Activity Index (CDAI), biochemical markers, and endoscopic and radiographic methods. Faecal calprotectin concentration was assessed in single stool samples by using the ELISA method.ResultsAmong all patients, 54 (45%) had ileocolonic CD location, 44 (36.5%) had isolated small bowel location, and 22 (18.5%) had colonic CD location. FC correlated significantly with C-reactive protein concentration and endoscopic and radiographic activity among patients with isolated small bowel CD (p = 0.03, r = 0.32; p < 0.0001, r = 0.78; p = 0.03, r = 0.35; respectively) and with C-reactive protein and endoscopic activity in isolated colonic CD (p = 0.0009, r = 0.7; p = 0.0002, r = 0.78; respectively). CDAI and inflammatory biochemical markers did not correlate with endoscopic and radiographic assessment in small bowel CD. In patients with ileocolonic CD, FC correlated significantly with endoscopy (p = 0.006, r = 0.5), radiographic assessment (p = 0.04, r = 0.3), CDAI (p = 0.0006, r = 0.5) and the majority of biochemical markers.ConclusionsFaecal calprotectin is a useful diagnostic marker in all CD patients. Although its usefulness in small bowel CD seems to be the lowest, it should be utilized particularly in this disease location because of the lack of other reliable, non-invasive diagnostic methods.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study

Stawczyk‐Eder¹,

Eder²,

Łykowska‐Szuber³

et al. 2015

aoms

Self Cite

View full text Add to dashboard Cite

show abstract

“…MaRIA allows to assess the CD activity both in the small and the large bowel. This is due to the fact, that in the aforementioned study the colon was additionally filled with warm water by inserting a flexible rectal balloon catheter, which gave a sufficient large bowel distension 8 10 . This is in contrast with the majority of MRE protocols, in which MRE imaging is performed completely noninvasively, focusing on the assessment of the small bowel CD activity.…”

Section: Discussionmentioning

confidence: 99%

“…The usefulness of MRE in CD diagnostics has been proved in many studies 5 6 7 . Moreover, there is an increasing number of scoring systems quantifying CD activity in MRE 8 9 10 . It has been also shown, that MR imaging can be very helpful in monitoring anti-TNF therapy in CD patients 11 12 13 .…”

mentioning

confidence: 99%

Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies

Eder

Michalak

Katulska

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

The aim of the study was to assess the role of magnetic resonance enterography (MRE) in predicting one-year efficacy of anti-tumor necrosis factor antibodies - infliximab (IFX), adalimumab (ADA) in Crohn’s disease (CD) patients primarily responding to therapy. We performed retrospective analysis among 61 CD patients who had undergone a successful IFX/ADA induction therapy and were treated with maintenance doses. All patients underwent MRE at week 0. We assessed which MRE features were predictive for steroid-free remission at week 52, and which were associated with a secondary loss of response. 44 patients were in steroid-free remission at week 52, 17 - were secondary non-responders. The ROC curve showed that bowel thickening with contrast enhancement analyzed together at week 0 were associated with steroid-free remission at week 52 (p = 0.01; AUC 0.67). Bowel stenosis with or without prestenotic dilatation [OR 5.8 (95% CI 1.4 – 25) and 2.4 (95% CI 1.2 – 5) respectively; p = 0.01] and the presence of intra-abdominal fistulas [OR 1.4 (95% CI 1.1 – 2); p = 0.004] were related to secondary non-response. A high baseline inflammatory activity detected by MRE predicts one-year response in CD after IFX/ADA. In case of bowel stenosis, intra-abdominal fistulas, other therapeutic options should be considered.

show abstract

“…Remission of the disease was defined as colonic SES-CD ≤ 3 points. The disease activity in the small intestine was evaluated in MRE by using an authorized score-Simple Enterographic Activity Score for Crohn's Disease (SEAS-CD) ( Table 3) [26]. Remission of the disease was present when the score was ≤ 6 points.…”

Section: Methodsmentioning

confidence: 99%

The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity

Klimczak

Łykowska‐Szuber

Eder

et al. 2015

European Journal of Internal Medicine

Self Cite

View full text Add to dashboard Cite

Simple Enterographic Activity Score for Crohn’s Disease: comparison with endoscopic, biochemical, and clinical findings

Cited by 12 publications

References 13 publications

Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study

Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study

Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies

The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity

Contact Info

Product

Resources

About